This article is more than 5 years old. Information may no longer be current.
Temozolomide plus bevacizumab well-tolerated in hemangiopericytomas and malignant solitary fibrous tumors
Park MS. Cancer. 2011;doi:10.1002/cncr.26098.
Results from a small retrospective study of patients with hemangiopericytomas and malignant solitary fibrous tumors suggest that the combination of temozolomide and bevacizumab is well-tolerated and may provide clinical benefit.
Hemangiopericytomas and solitary fibrous tumors (HPC/SFT) are closely related soft tissue sarcomas that appear to exhibit fibroblastic-type differentiation and typically affect adults aged 20 to 70 years. These tumors can appear anywhere in the body, but are most commonly found in the lower extremities, retroperitoneum/pelvis, lung/pleura and meninges.
Researchers at The University of Texas MD Anderson Cancer Center reviewed the records of 14 patients treated for HPC/SFT from May 2005 to June 2007. All patients were assigned to 150 mg/m2 temozolomide (Temodar, Schering-Plough) and 5 mg/kg IV bevacizumab (Avastin, Genentech).
The objective response rate was 79% (95% CI, 49.2-95.3) at a median of 34 months’ follow-up. Researchers determined that all responding patients had Choi partial response. Two patients (14%) had Choi stable disease and one patient had progressive disease. Median time to response was 2.5 months.
One patient had a reduction in tumor size, three had reductions in tumor density and seven patients had both. Ten patients (71%) showed some degree of tumor shrinkage with a median decrease of 10.1%.
Ten patients demonstrated reduction in tumor density of at least a 15%. The median percent decrease in density was 26.2%.
All patients had discontinued therapy at the time of this analysis. Six patients discontinued for disease progression, two others developed thrombocytopenia and one patient discontinued due to fungal infection.
 |
Follow HemOncToday.com on Twitter. |